What have we learned from basic science studies on idiopathic pulmonary fibrosis?

Toyoshi Yanagihara, Seidai Sato, Chandak Upagupta and Martin Kolb

ABSTRACT

Idiopathic pulmonary fibrosis is a fatal age-related lung disease characterised by progressive and irreversible scarring of the lung. Although the details are not fully understood, there has been tremendous progress in understanding the pathogenesis of idiopathic pulmonary fibrosis, which has led to the identification of many new potential therapeutic targets. In this review we discuss several of these advances with a focus on genetic susceptibility and cellular senescence primarily affecting epithelial cells, activation of profibrotic pathways, disease-enhancing fibrogenic cell types and the role of the remodelled extracellular matrix.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a median survival time of 3–5 years after diagnosis [1, 2]. It is an age-related disease, with the vast majority of individuals being diagnosed at >60 years of age [1]. IPF is associated with exertional dyspnoea, chronic cough, declining lung function and impairment in quality of life. Many patients with IPF experience acute exacerbations and acute episodes of respiratory worsening, associated with up to 50% mortality rate [3, 4].

Formerly regarded as a result of chronic inflammation, clinical trials with a combination of anti-inflammatory drugs (prednisone, azathioprine and N-acetyl-L-cysteine) failed to improve outcomes [5].

In recent decades, though not fully understood in detail, there has been tremendous progress in understanding the pathogenesis of IPF. The current hypothesis is that subclinical alveolar epithelial injury imposed on ageing epithelial cells in genetically susceptible individuals leads to aberrant wound healing, secretion of high levels of growth factors, cytokines, chemokines, accumulation of fibroblasts and differentiation into myofibroblasts, and deposition of the extracellular matrix (ECM). To date, two drugs for IPF are available, pirfenidone and nintedanib, both slowing disease progression [6]. Other investigational therapies currently target many of the mediators and signalling pathways involved in the pathogenesis of pulmonary fibrosis (table 1) [7].
In this review, we highlight some of the current knowledge of the pathogenesis of IPF from basic science and describe how these may have an impact on potential future therapies for this devastating lung disease.

Genetic susceptibility

For decades, case series of pulmonary fibrosis occurring in families suggested a genetic predisposition to this disease. These heritable pulmonary fibrosis forms are called familial interstitial pneumonia (FIP) and have been investigated in detail to try and understand the pathogenesis of IPF. A breakthrough occurred in 2001, when NOGEE et al. [8] identified a heterozygous mutation in the SFTPC gene, encoding surfactant protein (SP)-C. Subsequently, additional mutations in SFTPC were reported [9–11]. Furthermore, mutations in SFTPA2, encoding SP-A2 in FIP and sporadic IPF, and mutations in SFTPA1, encoding SP-A1 in FIP, were identified [12–14]. Expression of mutant SFTPC proteins in human alveolar epithelial cells (AECs) led to the aggregation of mutated SP-C protein in the endoplasmic reticulum and increased endoplasmic reticulum stress [15]. Transgenic mice expressing mutant L188Q SP-C found in FIP, exclusively in type 2 AECs, showed endoplasmic reticulum stress and exaggerated lung fibrosis after bleomycin administration [16]. Transgenic mice expressing mutant I73T SFTPC in type 2 AECs developed spontaneous lung fibrosis [17]. These findings indicate that endoplasmic reticulum stress in type 2 AECs, increased by the mutant SP-C protein, contributes to fibrogenesis. Similarly, SP-A2 mutant proteins (G231V and F198S) remaining within the endoplasmic reticulum enhance endoplasmic reticulum stress [12, 18]. SP mutations reportedly account for no more than 5% of sporadic IPF but considering that both SP-A and SP-C are produced exclusively by type 2 AECs, these studies still provide strong evidence that recurrent epithelial cell injury is a major factor in IPF pathogenesis.

In 2011, a large genome-wide linkage study of patients with IPF identified a common single nucleotide polymorphism (SNP) (rs35705950) in the promoter region of MUC5B associated with a 20-fold increased risk of IPF in subjects who were homozygous for the SNP (seven-fold in heterozygous subjects) [19]. These findings have been replicated in several studies since the first report [20–23]. While at least one copy of the variant seems to be present in 34–38% of patients with IPF, it also is present in 9% of healthy controls. Interestingly, the rs35705950 variant is associated with some forms of fibrotic interstitial lung diseases (rheumatoid arthritis-related interstitial lung disease and chronic hypersensitivity pneumonitis) [24, 25] but not associated with a variety of other fibrotic interstitial lung diseases (scleroderma-related interstitial lung disease, asbestosis, sarcoidosis) [22, 23, 26], suggesting a specific role for the variant in the pathogenesis of pulmonary fibrosis. The frequencies of the T-allele at rs35705950 is different among ancestries (European: 11%, South Asian: 8%, East Asian: 1%, African: <1%) [27]; the risk associated with

| Target molecules | Agent (company) | ClinicalTrials.gov or JAPIC identifier |
|------------------|----------------|---------------------------------------|
| Galectin-3       | TD139 (Balecto Biotech) | NCT02257177 |
| Autotaxin        | GLPG1690 (Galapagos NV) | NCT03711162 |
| GPR84            | GLPG1205 (Galapagos NV) | NCT03725852 |
| GPR40 and GPR84  | PBI-4050 (ProMetic BioSciences, Inc.) | NCT02538536 |
| PDE, 5-LO, LT, phospholipase C and thromboxane A2 | Tripelukast (MediciNova) | NCT02503657 |
| Integrin αvβ6    | BG00011 (Biogen) | NCT03573505 |
| Pentraxin-2      | PRM-151 (Promedior, Inc.) | NCT02550873 |
| Rho-associated kinase 2 | KD025 (Kadmon Corporation, LLC) | NCT02688647 |
| Connective tissue growth factor | FG-3019 (FibroGen) | NCT01262001 |
| c-Jun N-terinal kinase | CC-90001 (Cellgene) | NCT03142191 |
| Nrf2             | Bardoxolone methyl [Reata Pharmaceuticals] | NCT02036970 |
| Receptor for B-cell activating factor of the TNF family | VAY736 (Novartis) | NCT03287414 |
| Heat shock protein 47 | ND-L02-s0201 (Nitro BioPharma) | NCT03538301 |
| Somatostatin     | Ocreotide [Novartis Pharma] | NCT00463983 |
| VEGFR, MET, FMS and PDGFR | TAS-115 (Taiho Pharma) | JapicCTI-183898 |

PDE: phosphodiesterase; 5-LO: arachidonate 5-lipoxygenase; LT: leukotriene; TNF: tumour necrosis factor; VEGFR: vascular endothelial growth factor receptor; MET: hepatocyte growth factor receptor; FMS: Feline McDonough Sarcoma oncogene; PDGFR: platelet-derived growth factor receptor.
become a novel therapeutic strategy.

These exciting findings suggest that promotion of mitophagy may reduce mitochondrial damage and could improve survival. The treatment with thyroid hormone promoted the expression of PINK1, resulting in bleomycin-induced lung fibrosis and delivery of aerosolised thyroid hormone resolved fibrosis and enzyme that activates thyroid hormone, were higher in IPF lungs.

Mitochondrial dysfunction
Mitochondrial dysfunction contributes to the pathogenesis of several age-related diseases, including IPF [49, 50]. In IPF lungs, AECs exhibit large numbers of damaged mitochondria [51], and increased levels of free mitochondrial DNA were found in the plasma and bronchoalveolar lavage of patients with IPF [52]. Special attention has been paid to mitophagy in regulating cell fate for both AECs and fibroblasts. Mitophagy describes the selective lysosomal degradation of damaged mitochondria and is mainly governed by a signalling molecule called PINK1 [53]. Decreased expression of PINK1 in type 2 AECs was found in IPF lungs and correlated with the accumulation of dysmorphic mitochondria and increased AEC apoptosis [51]. In 2018, Yu et al. [54] reported that the activity and expression of iodothyronine deiodinase 2 (DIO2), an enzyme that activates thyroid hormone, were higher in IPF lungs. Dio2-deficient mice exhibited enhanced bleomycin-induced lung fibrosis and delivery of aerosolised thyroid hormone resolved fibrosis and improved survival. The treatment with thyroid hormone promoted the expression of PINK1, resulting in the restoration of normal mitochondrial function and rescue from mitochondria-regulated apoptosis [54]. These exciting findings suggest that promotion of mitophagy may reduce mitochondrial damage and could become a novel therapeutic strategy.

Profibrotic mediators
Dysfunctional AECs produce numerous mediators that promote migration of cells (such as fibrocytes, monocytes and fibroblasts) and induce their differentiation into fibrogenic cell types such as myofibroblasts. These fibrogenic cells are responsible for the accumulation of excessive amounts of ECM.
which eventually destroys the lung architecture. Transforming growth factor (TGF-β), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), endothelin-1, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and CXC chemokine ligand 12 (CXCL12) are all secreted by type 2 AECs and promote profibrotic responses.

Among these factors, TGF-β is the most potent profibrotic mediator. TGF-β promotes AEC apoptosis, epithelial-mesenchymal transition, production of other profibrotic mediators, recruitment of circulating fibrocytes and fibroblast transformation into myofibroblasts [55]. CTGF is a matricellular protein that mediates tissue remodelling and fibrosis, acting to promote fibroblast migration, the formation and activation of myofibroblasts and ECM deposition [56, 57]. Recently a clinical trial with FG-3019, a monoclonal anti-CTGF antibody, showed a slower decline in lung function for patients with IPF [58]. PDGF is a growth factor known to be a strong stimulus of proliferation, migration and survival of fibroblasts produced by AECs and macrophages [59, 60]. The FGF family has 22 structurally related members, interacting with heparin sulfate glycosaminoglycans, and binding to extracellular FGF receptors (FGFRs) [61]. FGFs and FGFRs also have very important roles in cell proliferation, differentiation, migration and survival [62]. Particularly, FGF-2 is a mitogen for fibroblasts and induces collagen synthesis [63]. In IPF lungs, FGF-2 is produced by alveolar macrophages, fibroblasts, endothelial cells and mast cells and increased FGF-2 levels are present in IPF lungs [64]. The VEGF family consists of five secreted members, with VEGF-A and -B playing an important role in the regulation of blood vessel growth, while VEGF-C and -D mainly affect lymphangiogenesis [65]. VEGFs bind to the three different VEGF receptors (VEGFRs). VEGF-A has been shown to stimulate PDGF receptor (PDGFRs), thereby regulating mesenchymal cell migration and proliferation [66]. Inhibition of VEGFR may reduce experimental fibrosis [67]. All these findings highlight a complex interaction between these growth factors, which is dysregulated in fibrotic lungs. Targeting just one of them may not result in the expected therapeutic effect, which may explain why several clinical trials with single targets did not report more positive results [7].

Nintedanib is a potent inhibitor of several receptor tyrosine kinases for PDGFR, FGFR and VEGFR, and has shown efficacy in reducing the decrease of forced lung capacity [68]. Pirfenidone also targets several growth factors involved in fibrogenesis and has also shown efficacy on slowing the progression of IPF [69, 70]. Thus, targeting profibrotic mediators, ideally several and not just one, can have therapeutic benefits for IPF.

**Disease modifying cells in IPF**

Dysfunctional AECs can induce the migration and accumulation of profibrotic cells. The following section highlights recent findings in such disease-enhancing cells in IPF.

**Fibroblasts**

Fibroblasts are tissue mesenchymal cells that are key in establishing and maintaining a normal and structured ECM. During wound healing, epithelial cell activation and epithelial-mesenchymal signalling induce the migration and activation of fibroblasts, differentiation to myofibroblasts, deposition and remodelling of ECM. Too much or aberrant activity of these processes can turn wound healing into scarring and fibrosis. Lysophosphatidic acid has been identified as a mediator of fibroblast chemoattractant activity [71], and administration of GLPG1690, an inhibitor of autotaxin, the enzyme principally responsible for extracellular lysophosphatidic acid production, showed a slower decline in lung function for patients with IPF [72] and is currently undergoing phase III clinical trials (ClinicalTrials.gov identifier: NCT03711162 and NCT03733444).

Several mediators, including TGF-β and PDGF, can drive the differentiation of fibroblasts to myofibroblasts. Myofibroblasts secrete large amounts of ECM molecules, including collagen [73], and this excess production together with reduced removal of ECM leads to pathologic lung remodelling and fibrosis. Furthermore, IPF fibroblasts seem to obtain a specific phenotype with increased capacity for invasion [74, 75] and resistance to apoptosis [76, 77], making them more destructive and detrimental in the lungs. In 2019, **Wohlfahrt et al.** [78] reported that the transcriptional factor PU.1 was an essential regulator of profibrotic gene expression in fibroblasts. In theory, targeting such apoptosis-resistant fibroblasts could be a promising strategy for novel therapies.

**Macrophages**

Macrophages are a pool of tissue-resident and circulating cells that can transform from one phenotype to another [79, 80]. Their classical phenotypes are ‘M1’ or ‘M2’ macrophages [81]. The polarisation of macrophages is a very dynamic process in which macrophages develop various functional phenotypes in response to stimulation and signals from the microenvironment they live in [82]. Macrophages are the most abundant immune cells in the lung, and they play important roles in tissue remodelling during pulmonary fibrosis [83]. M1 macrophages (‘classically activated macrophages’) contribute to the host defence against
bleomycin-induced lung injury [113]. Based on these facts, several clinical trials have been completed to

Recently, RAGHU mediated by suppression of fibrocyte function [108].

proliferation of fibroblasts and suggested that the antifibrotic effects of nintedanib are at least partly

$(\text{MIP})\text{-1}$

Indeed, fibrocytes produce numerous growth factors (e.g. macrophage colony-stimulating factor (M-CSF), TGF-β, FGF, PDGF and VEGF) and chemokines (e.g. IL-8 and macrophage inflammatory protein (MIP)-1α) [98, 107, 108]. Our group also showed that growth factors produced by fibrocytes promote the proliferation of fibroblasts and suggested that the anti-fibrotic effects of nintedanib are at least partly mediated by suppression of fibrocyte function [108].

 Recently, RAGHU et al. [109] reported that recombinant pentraxin 2 slowed the decline of lung function in patients with IPF in a phase II study. Biologically, pentraxin 2 inhibits monocyte differentiation into fibrocytes and is also a potent inhibitor of monocyte differentiation into proinflammatory macrophages [109]. Even though fibrocytes may reflect just a small cell population in the fibrotic process, these results are significant because they suggest that therapies targeting fibrocytes and macrophages hold promise and will be investigated in upcoming phase III trials.

Stem cells

Stem cells (e.g. mesenchymal stromal stem cells (MSCs), induced pluripotent stem cells and lung stem cells) have been proposed as a potential therapy for IPF due to their multipotency and role in tissue repair and wound healing. Stem cells produce antifibrotic mediators such as hepatocyte growth factor, FGF-1 and prostaglandin E2 [110–112], and MSCs have been found to elicit a protective effect in mice with bleomycin-induced lung injury [113]. Based on these facts, several clinical trials have been completed to
evaluate the safety and efficacy of MSCs in the treatment of IPF [114–116]. These trials concluded that both endobronchial or intravenous administration of stem cells are safe and well tolerated; however, the intervention efficacy of MSCs still needs to be investigated.

**ECM abnormality**

The lung ECM is constituted of collagens, elastin, glycoproteins, proteoglycans and other components, providing structural scaffolding for cells and mechanical stability of the organ. The ECM also serves as a reservoir for growth factors. In IPF lungs, however, the ECM is extensively modified, which results not only in destruction of lung architecture, but also excessive storage of fibrogenic mediators. The ECM abnormalities in fibrotic lungs are related to its biomechanical and biochemical properties. ECM stiffness itself contributes to the progression of IPF. The de-cellularised IPF matrix is significantly stiffer than the normal lung matrix [117]. When fibroblasts are cultured on stiff matrices or de-cellularised IPF lungs, they differentiate into activated myofibroblasts characterised by increased α-smooth muscle actin and decreased prostaglandin E2 expression, which are features of IPF myofibroblasts [117–119]. Rho kinase (ROCK) has a role in this phenotypic change by mechanotransduction. *In vitro* studies showed that ROCK potently stimulates the differentiation of fibroblasts into myofibroblasts [120], and a ROCK inhibitor demonstrated a therapeutic effect in the pulmonary fibrosis model [121]. KD025, a selective ROCK2 inhibitor, is currently in early clinical development (*ClinicalTrials.gov* identifier: NCT02688647). It seems to be well tolerated and even showed reduced decline of forced lung capacity in a small trial in patients with IPF [122].

Most molecules within the ECM are dynamically turned over and the whole ECM structure is constantly remodelled. In IPF, this remodelling is dysregulated; increased deposition of the individual ECM components partnered with reduced degradation leads to matrix accumulation and fibrosis [117, 123]. ECM fragments such as fibrin, fibronectin and hyaluronan are drastically upregulated in fibrotic ECMs, and have profibrotic effects similar to growth factors [124], suggesting that the compositional changes of the fibrotic ECM alone can drive a profibrotic cell phenotype.

Matrix components have a constant interaction with growth factors, including TGF-β and CTGF. TGF-β is secreted in an inactive form and is bound to latent-associated peptide which prevents interaction with its receptors. Latent-associated peptide is targeted by numerous mediators and proteins including matrix metalloproteinases, which leads to its proteolytic degradation and release of TGF-β. Integrins, especially αVβ6, are known to bind and activate latent TGF-β. Administration of anti-αVβ6 integrin antibodies protects against bleomycin-induced pulmonary fibrosis in mice [125]. A recent proof-of-concept trial with BG00011, a humanised monoclonal antibody against αVβ6 integrin in patients with IPF showed inhibition of phosho-SMAD2 levels in bronchoalveolar lavage cells [126]. These results were encouraging enough to perform a larger study of BG00011 in patients with IPF (*ClinicalTrials.gov* identifier: NCT03573505).

Mechanical force-induced activation of TGF-β is another important mechanism highlighting the influence of increased tissue and ECM stiffness on cell phenotypes. Recent experiments performed by our group showed that mechanical stretch activates and releases TGF-β in living tissues from fibrotic lungs [127]. This work suggested that even relatively mild mechanical forces, such as distention of the lung tissue during tidal volume breathing, might contribute to progression of IPF through activation of fibrogenic growth factors [128].

**Limitations in basic research**

*In vitro* and *in vivo* models are invaluable for understanding the pathomechanisms in IPF; however, these models have limitations. One example is the difficulty in culturing human primary AECs, which makes *in vitro* testing challenging. Furthermore, several animal models of IPF, including bleomycin-induced lung fibrosis, fail to fully recapitulate IPF as seen in patients. Despite this, basic science contributes to the field by generating novel *ex vivo* lung models such as induced pluripotent stem cell-generated AECs [129], precision-cut *ex vivo* lung models [130], lung-on-chip technologies [131] and gene-engineered mice. These systems will be important to appropriately study lung fibrosis and develop effective therapies in the future.

**Conclusion**

IPF is a complex and progressive lung disorder with limited therapeutic options. Recent advances in the understanding of IPF pathogenesis support the concept that different biological processes are involved sequentially in the development of pulmonary fibrosis (figure 1). The heterogeneity of the disease and the unpredictable clinical behaviour further suggests that these different biological processes are present in one IPF lung at the same time, just in different areas. Chronic epithelial cell damage, most likely caused by as yet unidentified environmental exposures, develop in genetically susceptible individuals. Known genetic mutations or gene variants lead to epithelial cell dysfunction and accelerated ageing. Molecular mediators from dysregulated epithelial cells cause an accumulation of fibrogenic cells and myofibroblast differentiation.
These contribute to progression through aberrant ECM deposition. The remodelled lung architecture is composed of a biochemically and biomechanically abnormal matrix, which results in a cyclical loop of progressive fibrosis. Understanding these complex disease steps with their underlying biological basis is key to informing about the best combination of therapies to finally halt the progression of IPF.

Conflict of interest: T. Yanagihara reports personal fees from Prometic, outside the submitted work. S. Sato reports grants from Canadian Institute for Health Research, during the conduct of the study. C. Upagupta reports grants from Canadian Institute for Health Research, during the conduct of the study. M. Kolb reports grants from Canadian Institute for Health Research, during the conduct of the study; grants and personal fees from Roche, Boehringer Ingelheim and Prometic, grants from Actelion, Respivert and Alkermes, and personal fees from Genoa, Indalo and Third Pole, outside the submitted work.

Support statement: This study was funded by the Canadian Institutes of Health Research, Institute of Circulatory and Respiratory Health (MOP136950). Funding information for this article has been deposited with the Crossref Funder Registry.

References
1 Hopkins RB, Burke N, Fell C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. *Eur Respir J* 2016; 48: 187–195.
2 Raghu G, Chen S-Y, Yeh W-S, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. *Lancet Respir Med* 2014; 2: 566–572.

https://doi.org/10.1183/16000617.0029-2019
Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2011; 183: 431–440.

Kolb M, Bondue B, Pesce A, *et al.* Acute exacerbations of progressive-fibrosing interstitial lung diseases. *Eur Respir Rev* 2018; 27: 180071.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, *et al.* Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *N Engl J Med* 2012; 366: 1968–1977.

Raghu G, Rochebouët N, Zhang Y, *et al.* An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. *Am J Respir Crit Care Med* 2015; 192: e3–e19.

Sato S, Yanagihara T, Kolb MR. Therapeutic targets and early stage clinical trials for pulmonary fibrosis. *Expert Opin Investig Drugs* 2019; 28: 19–28.

Nogue LM, Dunbar AE, Wert SE, *et al.* A mutation in the surfactant protein C gene associated with familial interstitial lung disease. *N Engl J Med* 2001; 344: 573–579.

Thomas AQ, Lane K, Phillips J, *et al.* Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. *Am J Respir Crit Care Med* 2002; 165: 1322–1328.

van Moorsel CHM, van Oosterhout MFM, Barlo NP, *et al.* Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. *Am J Respir Crit Care Med* 2010; 182: 1419–1425.

Ono S, Tanaka T, Ishida M, *et al.* Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred. *Eur Respir J* 2011; 38: 861–869.

Wang Y, Kuan PJ, Xing C, *et al.* Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. *Am J Hum Genet* 2009; 84: 52–59.

van Moorsel CHM, Ten Klooster L, van Oosterhout MFM, *et al.* SFTPA2 mutations in familial and sporadic idiopathic interstitial pneumonia. *Am J Respir Crit Care Med* 2015; 192: 1249–1252.

Nathan N, Giraud V, Picard C, *et al.* Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. *Hum Mol Genet* 2016; 25: 1457–1467.

Mulgutete S, Nguyen V, Russo SJ, *et al.* A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. *Am J Respir Cell Mol Biol* 2005; 32: 521–530.

Lawson WE, Cheng D-S, Degryse AL, *et al.* Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. *Proc Natl Acad Sci* 2011; 108: 10562–10567.

Nureki S-I, Tomer Y, Venosa A, *et al.* Expression of mutant SFTPC in murine alveolar epithelia drives spontaneous lung fibrosis. *J Clin Invest* 2018; 128: 4008–4024.

Maitra M, Wang Y, Gerard RD, *et al.* Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. *J Biol Chem* 2010; 285: 22103–22113.

Seibold MA, Wise AL, Speer MC, *et al.* A common MUC5B promoter polymorphism and pulmonary fibrosis. *N Engl J Med* 2011; 364: 1503–1512.

Fingerlin TE, Murphy E, Zhang W, *et al.* Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. *Nat Genet* 2013; 45: 613–620.

Noth I, Zhang Y, Ma SF, *et al.* Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. *Lancet Respir Med* 2013; 1: 309–317.

Stock CJ, Sato H, Fonseca C, *et al.* Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. *Thorax* 2013; 68: 436–441.

Borie R, Creustani B, Dieude P, *et al.* The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. *PLoS One* 2013; 8: e07621.

Ehstein E, Dromer C, Buendia-Roldan I, *et al.* MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. *N Engl J Med* 2018; 379: 2209–2219.

Arnould I, Batra K, Wolters P, *et al.* The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. *Lancet Respir Med* 2017; 5: 639–647.

Peltjo AL, Steele MP, Fingerlin TE, *et al.* The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonitis in systemic sclerosis. *Chest* 2012; 142: 1584–1588.

Austen A, Abecasis GR, Alshuler DM, *et al.* A global reference for human genetic variation. *Nature* 2015; 526: 68–74.

Horimasa Y, Oshhimo S, Bonella F, *et al.* MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis. *Respirology* 2015; 20: 439–444.

Wang G, Zhuang Y, Guo W, *et al.* Mucin 5B promoter polymorphism is associated with susceptibility to interstitial lung diseases in Chinese males. *PLoS One* 2014; 9: e104919.

Peltjo AL, Selman M, Kim DS, *et al.* The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. *Chest* 2015; 147: 460–464.

Hunninghake GM, Hatabu H, Okajima Y, *et al.* MUC5B promoter polymorphism and interstitial lung abnormalities. *N Engl J Med* 2013; 368: 2192–2200.

Peltjo AL, Zhang Y, Fingerlin TE, *et al.* Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. *JAMA* 2013; 309: 2232–2239.

Roy MG, Livraghi-Butrico A, Fletcher AA, *et al.* Muc5b is required for airway defence. *Nature* 2014; 505: 412–416.

Nakano Y, Yang IV, Waits AD, *et al.* MUC5B promoter variant rs55709590 affects MUC5B expression in the distal airways in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2016; 193: 464–466.

Yang IV, Fingerlin TE, Evans CM, *et al.* MUC5B and idiopathic pulmonary fibrosis. *Ann Am Thorac Soc* 2015; 12: Suppl. 2, S193–S199.

Hancock LA, Hennessy CE, Solomon GM, *et al.* Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice. *Nat Commun* 2018; 9: 5363.

Levy D, Neuhausen SL, Hunt SC, *et al.* Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. *Proc Natl Acad Sci USA* 2010; 107: 9293–9298.
Klingberg F, Hinz B, White ES. The myofibroblast matrix: implications for tissue repair and fibrosis. Proc Natl Acad Sci USA 2008; 105: 13051–13056.

Cronkite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 729–737.

Alder JK, Barkauskas CE, Limjunnyawong N, et al. Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci USA 2015; 112: 5099–5104.

Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutant carriers with pulmonary fibrosis. Eur Respir J 2014; 44: 178–187.

Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009; 114: 2236–2243.

Ziegler P, Schrenzenmeier H, Akkad J, et al. Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation. Ann Hematol 2012; 91: 1115–1120.

Towsley DM, Dumitriu B, Liu D, et al. Danazol treatment for telomerase diseases. N Engl J Med 2016; 374: 1922–1931.

Mora AL, Bueno M, Rojas M. Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis. J Clin Invest 2017; 127: 405–414.

Tsubouchi K, Araya J, Kuwano K. PINK1-Parkin-mediated mitophagy in COPD and IPF pathogenesis. Inflamm Regen 2018; 38: 18.

Bueno M, Lai YC, Romero Y, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest 2015; 125: 521–538.

Ryu C, Sun H, Gulati M, et al. Extracellular mitochondrial DNA is generated by fibroblasts and predicts death in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017; 196: 1571–1581.

Youle RJ, Narendran DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011; 12: 9–14.

Yu G, Tzouvelekis A, Wang R, et al. Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nat Med 2018; 24: 39–49.

Grimminger F, Günther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1426–1433.

Lipson KE, Wong C, Teng Y, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 2012; 5: S24.

Ramazani Y, Knops N, Elmonem MA, et al. Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biol 2018; 68–69: 44–66.

Raghu G, Scholand MB, De Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47: 1481–1491.

Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276–1312.

Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 255–273.

Olsen SK, Garbi M, Zampieri N, et al. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem 2003; 278: 34226–34236.

Boilly B, Verscouer-Edouart AS, Hondermarck H, et al. FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev 2000; 11: 295–302.

Chen Y, Zhao M, Fu M, et al. The role of calcineurin in the lung fibroblasts proliferation and collagen synthesis induced by basic fibroblast growth factor. Chin Med J 2003; 116: 857–862.

Inoue Y, King TE, Tinkle SS, et al. Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol 1996; 149: 2037–2054.

Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437: 169–183.

Ball SG, Shuttleworth CA, Kiely GM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007; 177: 489–500.

Hamada N, Kuwano K, Yamada M, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005; 175: 1224–1231.

Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1434–1445.

Davis S, Rafia R, Carroll C, et al. Pirfenidone for treating idiopathic pulmonary fibrosis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics 2019; 37: 763–775.

Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291: 367–373.

Tager AM, LaCamera P, Shea BS, et al. The lysosphosphatic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14: 45–54.

Maher TM, van der Aar EM, Van de Steen O, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med 2018; 6(6): 1–9.

Klingberg F, Hinz B, White ES. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol 2013; 229: 298–309.

Li Y, Jiang D, Liang J, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med 2011; 208: 1459–1471.

Geng Y, Liu X, Liang J, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight 2019; 4: 123526.
Jiang D, Liang J, Fan J, Zhang L, Wang Y, Wu G, Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. Immunity 2014; 40: 344–349.

Scott CL, Henri S, Guilhams M. Mononuclear phagocytes of the intestine, the skin, and the lung. Immunol Rev 2014; 262: 9–24.

Mantovani A, Sica A, Sozanni S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677–686.

Locati M, Mantovani A, Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol 2013; 120: 163–184.

Murray PJ. Macrophage polarization. Annu Rev Physiol 2017; 79: 541–566.

Cai Y, Sugimoto C, Arainga M, Murray PJ, et al. In vivo characterization of alveolar and interstitial lung macrophages in rhesus macaques: implications for understanding lung disease in humans. J Immunol 2014; 192: 2821–2829.

Saradna A, Do DC, Kumar S, Kleaveland KR, Velikoff M, Yang J, Sisson TH, Maher TM, Ajayi IO, Scott CL, Henri S, Guilliams M. Mononuclear phagocytes of the intestine, the skin, and the lung. Immunol Rev 2014; 262: 9–24.

Zhao Y, Wang Y, Zhang Z, et al. Macrophages: friend or foe in idiopathic pulmonary fibrosis? Respir Res 2018; 19: 170.

Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173–1179.

Samara KD, Antoniou KM, Karagiannis K, et al. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. Int J Oncol 2012; 40: 1397–1404.

Zhong B, Yang X, Sun Q, et al. Pdc4 modulates markers of macrophage alternative activation and airway remodeling in antigen-induced pulmonary inflammation. J Leukoc Biol 2014; 96: 1065–1075.

Ayaub EA, Dubey A, Imani J, et al. Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis. Sci Rep 2017; 7: 13281.

Yao Y, Wang Y, Zhang Z, et al. Chop deficiency protects mice against bleomycin-induced pulmonary fibrosis by attenuating M2 macrophage production. Mol Ther 2016; 24: 915–925.

Van Dyken SJ, Locksley RM. Interleukin-4 and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Ann Rev Immunol 2013; 31: 317–343.

Reyfman PA, Walter JM, Joshi N, et al. Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am J Respir Crit Care Med 2019; 199: 1517–1536.

Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 2019; 20: 163–172.

van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. J Exp Med 1968; 128: 415–435.

Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. Immunity 2016; 44: 439–449.

Misharin AV, Morales-Nebreda L, Reyfman PA, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp Med 2017; 214: 2387–2404.

Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol 2011; 11: 427–435.

Yang L, Scott PG, Giuffre J, et al. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest 2002; 82: 1183–1192.

Andersson-Sjöland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40: 2129–2140.

Mehrad B, Burdick MD, Zisman DA, et al. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007; 353: 104–108.

Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588–594.

Lama VN, Phan SH. The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc 2006; 3: 373–376.

Madala SK, Edukulla R, Schmidt S, et al. Bone marrow-derived stromal cells are invasive and hyperproliferative and alter transforming growth factor-α-induced pulmonary fibrosis. Am J Respir Crit Mol Biol 2014; 50: 777–786.

Moore BB, Kolodsiack JE, Thanmickal VJ, et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005; 166: 675–684.

Kleaveland KR, Velikoff M, Yang J, et al. Fibrocytes are not an essential source of type I collagen during lung fibrosis. J Immunol 2014; 193: 5229–5239.

Abe S, Okazaki H, Kishi M, et al. Fibrocyte regulates lung fibroblast activation. Am J Respir Crit Care Med 2012; 185: A4460.

Sato S, Shinohara S, Hayashi S, et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 2017; 18: 172.

Raghav G, van den Blink B, Hamblin MJ, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA 2018; 319: 2299–2307.

Gazdar A, Susuri N, Hostettler K, et al. HGF expressing stem cells in usual interstitial pneumonia originate from the bone marrow and are anti-fibrotic. PLoS One 2013; 8: e65453.

Gazdar A, Grad I, TamO L, et al. The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor. Stem Cell Res Ther 2014; 5: 1–11.

Dong LH, Jiang YY, Liu YJ, et al. The anti-fibrotic effects of mesenchymal stem cells on irradiated lungs via stimulating endogenous secretion of HGF and PGE2. Sci Rep 2015; 5: 8713.

Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33: 145–152.
Tzouvelekis A, Paspalariis V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. *J Transl Med* 2013; 11: 171.

Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. *Respirology* 2014; 19: 1013–1018.

Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial. *Chest* 2017; 151: 971–981.

Booth AJ, Hadley R, Cornett AM, et al. Acellular normal and fibrotic human lung matrices as a culture system for *in vitro* investigation. *Am J Respir Crit Care Med* 2012; 186: 866–876.

Liu F, Mih JD, Shea BS, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. *J Cell Biol* 2010; 190: 693–706.

Marinković A, Liu F, Tschumperlin DJ. Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts. *Am J Respir Cell Mol Biol* 2013; 48: 422–430.

Akhmetshina A, Dees C, Plecky M, et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. *Arthritis Rheum* 2008; 58: 2553–2564.

Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. *J Clin Invest* 2013; 123: 1096–1108.

Averill F, Albertson TE, Baratz DM, et al. A phase 2 trial of KD025 to assess efficacy, safety and tolerability in patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2018; 197: A5927.

Venkatesan N, Tsuchiya K, Kolb M, et al. Glycosyltransferases and glycosaminoglycans in bleomycin and transforming growth factor-β1-induced pulmonary fibrosis. *Am J Respir Cell Mol Biol* 2014; 50: 583–594.

Frangogiannis NG. Fibroblast-extracellular matrix interactions in tissue fibrosis. *Curr Pathobiol Rep* 2016; 4: 11–18.

Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation. *Am J Respir Crit Care Med* 2008; 177: 56–65.

Raghu G, Mouded M, Culver DA, et al. Randomized, double-blind, placebo-controlled, multiple dose, dose-escalation study of BG00011 (Formerly STX-100) in patients with idiopathic pulmonary fibrosis (IPF). *Am J Respir Crit Care Med* 2018; 197: A7785.

Froese AR, Shimbori C, Belaye P-S, et al. Stretch-induced activation of transforming growth factor-β1 in pulmonary fibrosis. *Am J Respir Crit Care Med* 2016; 194: 84–96.

Upagupta C, Shimbori C, Alsilmi R, et al. Matrix abnormalities in pulmonary fibrosis. *Eur Respir Rev* 2018; 27: 180033.

Tamošiūnas L, Hibaoui Y, Kalloža S, et al. Generation of an alveolar epithelial type II cell line from induced pluripotent stem cells. *Am J Physiol Lung Cell Mol Physiol* 2018; 315: L921–L932.

Alsafadi HN, Staab-Weijnitz CA, Lehmann M, et al. An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices. *Am J Physiol Lung Cell Mol Physiol* 2017; 312: L896–L902.

Konar D, Devarasetty M, Yildiz DV, et al. Lung-on-a-chip technologies for disease modeling and drug development. *Biomed Eng Comput Biol* 2016; 7: 17–27.